Alterity Therapeutics Limited ((ASX:ATH, NASDAQ:ATHE) today announced that its Board of Directors approved a ratio change of its American Depository Shares (ADSs) to Ordinary Shares (the “ADS Ratio”) from the current ADS Ratio of 1 ADS representing 60 Ordinary Shares to 1 ADS representing 600 Ordinary Shares (the “ADS Ratio Change”). The ADS Ratio Change will be effective on January 9, 2023. Beginning with the opening of trading on Monday, January 9, 2023, Alterity’s ADS will continue to trade on the Nasdaq Capital Market under the symbol “ATHE,” but will trade on a split-adjusted basis under a new CUSIP number 02155X205.
Jefferies Maintains Hold on Jakks Pacific, Lowers Price Target to $14
Jefferies analyst Stephanie Wissink maintains Jakks Pacific (NASDAQ:JAKK) with a Hold and lowers the price target from $15 to $14.
_2-260x195.jpeg)
